The study aimed to evaluate the effect of the Biofield Energy Treated test formulation on the function of different vital organs viz. bones, heart, liver, lungs, and brain in multiple cell-based assays. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Lauree Ann Duprey-Reed, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI), BT-Med + UT-TI, and BT-Med + BT-TI groups showed 81.1% (at 1μg/mL), 78.4% (at 63μg/mL), and 87.9% (at 63μg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med+ BT-TI group showed 80.4% and 89.9% restoration of cell viability at 0.1 and 1 μg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 181.3%, 93.2%, and 90.7% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 25, and 63 μg/mL, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 102.6%, 80.5%, and 100.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10μg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 40% (at 10μg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 156.2%, 80.1%, and 137.0% in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups, respectively at 0.1μg/mL compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.1% and 105.0% in the UT-Med + BT-TI and BTMed + BT-TI groups, respectively at 25 μg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 30.4% and 51.9% in the BT-Med + BT-TI group at 30 and 63 μg/mL, respectively compared to untreated in A549 cells. Serotonin level was significantly increased by 67.9% and 42.3% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1μg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 136.8%, 191.9%, and 165.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 μg/mL compared to the untreated in MG-63 cells. Overall, the study outcomes suggest that the Biofield Energy Treated novel proprietary test formulation significantly improved the vital functional enzyme biomarkers relevant to bones, heart, liver, lungs, and brain. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.